New Framework Anticipates More Anti-monopoly Cases In China
This article was originally published in PharmAsia News
Executive Summary
China's Supreme People's Court released guidance that makes it easier for civilians to file anti-monopoly cases against pharmaceutical companies and other industries.
You may also be interested in...
What Does China's Price Manipulation Ruling On Unilever Mean For Global Pharma? (Part 1 of 2)
SHANGHAI - The National Development and Reform Commission, China's state planning agency, charged consumer goods company Unilever a fine of RMB 2 million ($310,000) for price manipulation May 6. The NDRC action was taken in an effort to suppress consumer inflation, but a key takeaway, according to experts, is that multinational companies should be cautious about how they communicate pricing information to the market or they may find themselves in violation of China's Price Law, Anti-Monopoly Law or even foreign antitrust and anti-bribery rules
Shiseido Unveils Strategy For Returning Company To Growth In 2013
Shiseido has strategic initiatives planned for its domestic and Chinese businesses and Bare Escentuals in the U.S. following a disappointing fiscal 2012 in which the Toyko-based firm recorded a net loss of $148 million.
Newhall Laboratories Works To Refresh Venerable Personal-Care Brands
La Bella, L.A. Looks and Soft & Dri have new websites and new marketing strategies behind them as Newhall Laboratories endeavors to rejuvenate personal-care brands it’s acquired over the past year and a half.